Ensifentrine vs placebo for chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized clinical trials

Overview of attention for article published in Expert Review of Respiratory Medicine, April 2025

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 4,367 followers.

Congratulations team!! #MedTwitter check this one out 👇🏻 https://t.co/HGJw3oGhXK

Ensifentrine, a new player in the COPD treatment landscape, shows promising clinical outcomes across a cohort of 2,589 patients. Many thanks to Dr. Aljazeeri for his mentorship, @carvalhalgiulia for her incredible leadership, and to the @metaacademy_of…

Thrilled to share that our meta-analysis on ensifentrine in COPD has been published! I am very grateful to my mentor, Dr. Aljazeeri, and all my amazing collaborators! Looking forward to our next projects! https://t.co/lxjIUMsY9m Thanks @metaacademy_…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.